73 results about "Digestive disorder" patented technology

The invention provides a method for establishing a diagnosis and treatment system for digestive system disease multi-modal information. The method comprises the following steps: S1, collecting multi-modal information for labeling and preprocessing; s2, extracting a feature vector and embedding a label into the multi-modal information according to the labeled information; s3, splicing and mapping the feature vector and the tag to a unified dimension to obtain an enhanced feature vector; s4, fusing the enhanced feature vectors to form a multi-modal feature matrix, performing linear mapping and weighted aggregation on the multi-modal feature matrix to obtain global fusion vectors, and collecting to generate a fusion vector sequence; s5, enhancing the time sequence information of the global fusion vector sequence, enhancing the spatial information of the spatial relevance of the specific feature of the part, and performing interactive fusion to obtain a spatio-temporal joint feature; s6, performing classification prediction on the disease stage or the specific pathological type, and outputting a diagnosis result; and S7, performing semantic association on the diagnosis result and the medical knowledge graph, sharing data to an online health intelligent platform, and providing a personalized decision basis for clinicians.

The invention relates to the technical field of the Internet of Things, and discloses an animal physiological feature data acquisition system and analysis method based on the Internet of Things, and the method comprises the following steps: cleaning and standardizing original sensor data, including filling missing data, eliminating noise interference through a dynamic filtering technology, unifying the dimension of multi-source data, and analyzing the data; the method comprises the following steps of: acquiring a Beidou time service time reference, eliminating redundant features, interpolating and aligning asynchronous sampling data to the Beidou time service time reference, correcting a time sequence phase difference of physiological and behavior data through a dynamic path matching technology, and correcting GPS / Beidou positioning drift in combination with Kalman filtering. Through multi-source sensing fusion and an edge-fog-cloud cooperative computing architecture, the effective collection rate of animal physiological data is achieved, abnormal response is delayed and compressed, the flexible energy supply technology and dynamic communication optimization are combined, the endurance and communication success rate is maintained in a pasture, and the false alarm rate is reduced compared with a traditional method; common diseases such as abnormal body temperature, digestive system diseases and the like are accurately warned and covered.

The invention belongs to the technical field of stem cells, and particularly relates to a product containing mesenchymal stem cells, a preparation method, a quality control method and application in prevention and treatment of digestive system diseases. According to the preparation method, 1-3 complete culture media are provided for culturing the mesenchymal stem cells, and the obtained mesenchymal stem cells are good in subpackage form; cD73, CD90 and CD105 are highly expressed, and CD19, CD34, CD45, CD11b and HLA-DR are not expressed; the cell proliferation capacity is strong, the osteogenesis and adipogenic differentiation capacity is strong, and the medicine is safe and free of toxic and side effects. The prepared mesenchymal stem cells are high in quality, have good performance of secreting HGF, KGF and IGF-1, and can effectively treat digestive system diseases.

The invention relates to the technical field of medical data processing, and discloses a gastrointestinal function outcome evaluation system for a digestive system disease patient, which comprises the following steps: firstly, obtaining gastrointestinal function index data of a to-be-tested person by using gastrointestinal ultrasonic image data of the to-be-tested person, and then evaluating the gastrointestinal function outcome of the to-be-tested person according to the gastrointestinal function index data of the to-be-tested person. Intestinal function ultrasonic monitoring index data (intestinal canal compression degree) and gastric function ultrasonic monitoring index data (gastric residual volume) of the person to be tested are obtained, and then a gastrointestinal function outcome evaluation result of the person to be tested is obtained. According to the gastrointestinal function outcome evaluation method, an accurate gastrointestinal function outcome evaluation result can be quickly obtained only by inputting the gastrointestinal ultrasonic image of the to-be-tested person into the gastrointestinal function outcome evaluation system of the patient with the digestive system disease, invasive examination does not need to be carried out on the to-be-tested person, the safety and comfort of the to-be-tested person in the gastrointestinal function outcome evaluation process can be greatly improved, and the accuracy of gastrointestinal function outcome evaluation is improved. And effective and reliable data are provided for scientific treatment decision making.

The invention aims to provide a preparation method of amnion-derived mesenchymal stem cells with high collagen expression. The preparation method comprises the following steps: step 1, reagents and materials: amnion tissues: obtaining a fresh amnion from a healthy puerpera after delivery; the PBS is used for cleaning amniotic tissues; collagenase: type I collagenase, which is used for digesting amniotic tissues to separate mesenchymal stem cells; a cell culture medium is a DMEM / F12 culture medium, and 10% of fetal calf serum and 1% of penicillin-streptomycin double antibodies are added; the transforming growth factor TGF-beta is used for promoting the expression of mesenchymal stem cell collagen; and the fibroblast growth factor FGF can assist in promoting cell proliferation and collagen expression. The invention aims to provide the preparation method of the amniotic membrane-derived mesenchymal stem cells for highly expressing collagen, and the amniotic membrane-derived mesenchymal stem cells can be widely applied to treatment of immune system diseases, reproductive system diseases, skin system diseases, skeletal system diseases, nervous system diseases, digestive system diseases, respiratory system diseases, circulatory system diseases and urinary system diseases. Particularly, the effects of immunosuppression and tissue repair are achieved.

The invention belongs to the technical field of pet food, and particularly relates to compound papain containing probiotics and application of the compound papain in pet digestion aiding products. The compound papain is prepared from active ingredients and auxiliary ingredients, wherein the active ingredients are mixed with the auxiliary ingredients; the active component is prepared from papain, bacillus subtilis protease and probiotics; the probiotics are prepared from lactobacillus acidophilus and bifidobacterium lactis. According to the compound papain disclosed by the invention, a double-enzyme design of papain and bacillus subtilis protease is adopted, so that the digestibility is remarkably improved, the digestion function of pets is favorably improved, nutrient substances in pet food are favorably absorbed, and the incidence rate of digestive system diseases is further favorably reduced. Besides, the double-probiotic design of lactobacillus acidophilus and bifidobacterium lactis is added on the basis of the double-enzyme design, so that the digestibility of the pet food can be further improved, the defect of adopting single protease or only depending on protease is overcome, and the method has a relatively good application prospect.

A method and apparatus for treating digestive system diseases, the method comprising: subcutaneously implanting a pulse generator and a plurality of electrodes into the abdomen of a patient, the plurality of electrodes being in electrical contact with a plurality of target areas of the abdomen of the patient; and applying an electrical stimulus to activate the plurality of target regions.

The application relates to a kind of intelligent question and answer methods of digestive system disease based on knowledge graph, specifically to disease learning and question and answer field, through fusing deep semantic understanding and knowledge graph reasoning, the accurate response of complex multi-round question and answer in digestive system disease field is realized;It first aligns the user dialogue with the medical knowledge graph in depth, dynamically focuses on the relevant knowledge subgraph, then explores the logically coherent reasoning path in the subgraph through reinforcement learning, and finally generates traceable answers based on the path and dialogue history;This process ensures that the reply is not only accurate in information, clear in logic, but also has good interpretability;More importantly, by feeding back the quality of the generated answer to the optimization process of the reasoning path, it realizes the end-to-end collaborative optimization from semantic understanding, knowledge retrieval, logical reasoning to language generation, significantly improving the overall performance and practicality of the system.

Helicobacter pylori (HP) is a chronic bacterium that infects the gastric mucosa. It is widespread in the general population, with an infection rate between 55% and 70%. HP is closely related to gastric ulcers and gastritis. Western medicine treatment for HP infection is relatively complex, including bismuth substituents and proton pump inhibitors plus two antibiotics. Gastric ulcers and gastritis are common digestive system diseases. Compound 1, "Exterminate the Ghost," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Scutellaria baicalensis and Fraxinus chinensis, which can eradicate HP. Compound 2, "Ulcer Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Rheum palmatum and Bletilla striata, which can cure gastric ulcers. Compound 3, "Gasitis Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Glycyrrhiza uralensis or Taraxacum mongolicum, made into a tea bag, which can cure chronic gastritis.

A composition including APsulloc 331261 (accession number: KCCM11179P) strain of Lactobacillus plantarum, a lysed product thereof, a culture thereof, an extract thereof, or mixtures thereof is disclosed. The composition has an activity of improving or treating disorders of the digestive system caused by alcohol or inflammation to facilitate the recovery of and improve the welfare of relevant patients. A method of preventing, improving, or treating gastrointestinal disorders by using the composition is disclosed.

The composition is prepared from the following raw materials in parts by weight: 20 to 40 parts of scorched hawthorn fruit, 5 to 15 parts of fried medicated leaven, 5 to 15 parts of rhizoma pinelliae, 3 to 7 parts of pericarpium citri reticulatae, 3 to 7 parts of fried semen raphani, 3 to 7 parts of endothelium corneum gigeriae galli, 5 to 15 parts of poria cocos, 3 to 7 parts of fructus forsythiae, 1 to 3 parts of fried malt, 0.5 to 1.5 parts of fructus foeniculi and 1 to 3 parts of chicken liver powder. The compound can be used for preparing drugs for treating canine digestive system diseases. According to the traditional Chinese medicine composition for dogs, the dietary structure and digestive physiological characteristics of dogs are optimized, rhizoma pinellinae praeparata is used, the use amount of malt is reduced, and the palatability of the prepared medicine is remarkably improved by matching with endothelium corneum gigeriae galli, fennel and chicken liver powder; meanwhile, compared with a traditional formula, the composition has the advantages that the apparent digestibility of the dogs is remarkably improved, the liver and kidney functions of the dogs are not remarkably influenced, and the composition is safe to take.

Apparatus and methods for providing therapeutic treatment for symptoms associated with GERD and / or other digestive disorders and / or other medical conditions are described herein. In some embodiments, an apparatus includes a base support having a support element portion and an encasement portion. The support element portion has a first end portion, a second end portion and a top surface disposed at an angle relative to a bottom surface. The second end portion has a height greater than the first end portion. A support pillow member is fixedly coupled to the base support between at least a portion of the encasement portion and at least a portion the second end portion of the support element portion. The support pillow member, the support element portion and the encasement portion collectively define an interior region that includes a receiving portion configured to receive at least a portion of a user's arm therein.

This invention discloses a traditional Chinese medicine composition comprising Codonopsis pilosula, Atractylodes macrocephala, Poria cocos, Glycyrrhiza uralensis (processed), Citrus reticulata peel, Torreya grandis, Citrus medica, Rosa rugosa, Hippophae rhamnoides, Kaempferia galanga, and Amomum tsao-ko. This composition is specifically designed for individuals requiring improved digestive function, aiming to address indigestion caused by factors such as irregular eating habits and excessive physical activity. This invention utilizes the synergistic effects of multiple traditional Chinese medicinal herbs to not only enhance digestive capacity but also improve the body's immune function. The efficacy and safety of this composition were demonstrated through tests on the general survival status, small intestinal propulsion rate, gastric emptying rate, gastrointestinal hormone levels, and immunoglobulin levels in rats. Therefore, this traditional Chinese medicine composition can serve as a novel treatment option, providing a natural, safe, and effective alternative therapy for patients with digestive disorders; it is also suitable as a daily health supplement to help maintain a healthy digestive system and strong immunity.

The invention relates to the technical field of biological medicine manufacturing, discloses an ancient herbal enzyme oral liquid for treating digestive system diseases and a preparation method, and aims to solve the problems that in the prior art, adaptability of strains and herbal fibers is insufficient, directional enzyme production induction is deficient, probiotic activity retention is poor, and a flora, fiber and enzyme cooperative closed loop cannot be constructed. The preparation method comprises the following steps: by taking genuine hemp seeds, Chinese herbaceous peony and the like as raw materials, matching with rhizosphere-separated saccharomyces cerevisiae Y-01, lactobacillus acidophilus L-03 and bacillus coagulans C-05, carrying out three-step directional fermentation of substrate pretreatment, flora colonization and enzymatic synthesis to produce CAZymes and SCFA, embedding probiotics through trehalose-chitosan, compounding a stabilizer adaptive preparation, and adjusting the ratio of the raw materials according to an IBS subtype. The fiber degradation efficiency and the functional product synthesis efficiency are improved, the gastric acid tolerance and the storage stability of the probiotics are enhanced, different IBS subtype requirements are met, and an effective means is provided for treatment of digestive system diseases.

The invention discloses a compound targeting AT1R, which is composed of a target head molecule targeting AT1R, a PEG linker, an aspartic acid linker and a chelating agent, and can be used as a component of a PET tracer agent targeting AT1R. A target head molecule can be embedded into a hydrophobic'pocket 'of AT1R protein, so that high-affinity and high-selectivity targeted binding is realized; the PEG connexon can prolong the residence time of the PET tracer agent targeting the AT1R at the tumor part; different numbers of aspartic acids can regulate and control the pharmacokinetic properties of the PET tracer agent targeting the AT1R, reduce the liver and gall and intestinal signal backgrounds of the PET tracer agent targeting the AT1R, and improve the target-to-cost ratio. Therefore, accurate diagnosis and treatment of digestive system diseases such as digestive tract tumor and liver cancer can be realized. The invention further discloses a PET tracer agent targeting AT1R as well as a preparation method and application of the PET tracer agent.

A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

The novel invention is based, at least in part. on the surprising finding that the combination of bacterial strains comprising P. freudenreichii JS27 and B. longum subsp. infantis, particularly B. longum subsp. infantis TPY12-1 can be used in medicine and / or as a food supplement when grown simultaneously. As such and as shown in the description and appended examples, growth and viability of bacterial strains possessing synergistic behavior can be enhanced in the human gut and thus can increase bioavailability as compared with alternative combinations of bacteria.

The invention provides immortalized adipose-derived mesenchymal stem cells as well as a preparation method and application thereof, and belongs to the technical field of cells, the preparation method comprises the following steps: separating adipose tissues, constructing cells to be screened by the obtained adipose-derived mesenchymal stem cells, and screening to obtain the immortalized adipose-derived mesenchymal stem cells; the immortalized adipose-derived mesenchymal stem cells are used for treating neurological diseases, respiratory system diseases, cardiovascular diseases, osteoarticular diseases, urinary system diseases, digestive system diseases, skin diseases or autoimmune diseases. According to the invention, by preparing the immortalized canine adipose-derived mesenchymal stem cells and utilizing an intranasal administration mode, the nervous system degenerative diseases can be safely and effectively relieved.

Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.

The invention relates to an inflammatory environment induced overexpression 1L-10 engineered macrophage and a construction method and application thereof, and belongs to the field of biomedicine.The construction method includes the steps that a recombinant plasmid for expressing IL-10 is constructed with a genetic engineering method, and an RAW264.7 macrophage is jointly transfected with the constructed recombinant plasmid for expressing IL-10 and a Cas9 plasmid, so that the engineering macrophage with the inflammatory environment induced overexpression 1L-10 is obtained, and the engineering macrophage with the inflammatory environment induced overexpression 1L-10 is obtained. According to the method, the IL-10 gene is used for replacing the position of the IL-1 gene in the RAW264.7 macrophage, so that the RAW264.7 macrophage can express IL-10 under the induction of an inflammatory environment, the constructed engineered macrophage is injected into the abdominal cavity of a colitis model mouse in an intraperitoneal injection manner, the macrophage is positioned to the colitis disease part and secretes an anti-inflammatory cytokine IL-10 due to the inflammatory chemotaxis of the macrophage, and the anti-inflammatory cytokine IL-10 is obtained. The effect of relieving intestinal inflammation is achieved. According to the invention, the development of ulcerative colitis treatment technology is facilitated, and the application of a macrophage-based cell treatment method in treatment of digestive system diseases is promoted.

Apparatus and methods for providing therapeutic treatment for symptoms associated with GERD and / or other digestive disorders and / or other medical conditions are described herein. In some embodiments, an apparatus includes a support element that has a first end portion and a second end portion and a top surface disposed at an angle relative to a bottom surface of the support element. The second end portion has a height greater than the first end portion. A riser element is configured to be coupled proximate to the second end portion of the support element. A body element is configured to be disposed on at least one of the support element or the riser element. The body element has a first arm and a second arm connected together by an arc portion.

An active yeast adapted to weak organic acids and to the use thereof for poultry or cud-chewing animals. Also, a probiotic for poultry or cud-chewing animals, including an active yeast adapted to weak organic acids. Further, the use of such a yeast for improving the zootechnical performances of poultry and to the use thereof in a probiotic and / or food for poultry. Furthermore, the use of such a yeast for improving the physico-chemical and fermentative parameters of the rumen of cud-chewing animals, and to the use thereof in a probiotic and / or food for cud-chewing animals. In addition, a yeast for use in the prevention and / or the treatment of digestive disorders in cud-chewing animals and particularly in the prevention of acidosis in cud-chewing animals.

Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using β-1,3 / 1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising β-1,3 / 1,6-D-glucan are also provided.

The invention relates to the technical field of traditional Chinese medicine diagnosis and treatment, in particular to a digestive system disease early prediction and diagnosis method based on traditional Chinese medicine constitution identification, which comprises the following steps of: establishing a diagnosis file of an interrogation individual, and then respectively acquiring constitution identification data through a scale identification method and a traditional four-diagnosis method; the method comprises the following steps: carrying out physique identification by referring to a knowledge graph of traditional Chinese medicine physique identification, shooting the face and the tongue of an interrogator through a shooting device, then carrying out pulse feeling and posture observation detection on the interrogator, and segmenting the shot images of the face and the tongue into a plurality of pictures; according to the method, the face and the tongue of an interrogator are shot and collected through shooting equipment, and then point-to-point form data matching is carried out on images of the face and the tongue and a traditional Chinese medicine constitution identification knowledge graph, so that efficient feature extraction and comparison are realized, feature states of the face and the tongue are obtained, and the feature states are used for judging the constitution type of the interrogator; the workload and difficulty of doctors are reduced, and the accuracy of physique identification is improved.

This invention belongs to the field of multi-omics data integration technology. It discloses a system for screening multiple disease biomarkers from the gut microbiota metabolome. The system performs batch-to-batch drift correction based on the comparison values ​​of internal reference metabolites on metabolomic mass spectrometry data from multiple disease and healthy control groups. Then, it calculates the covariant stability index between metabolites and microbial species, and constructs a constrained metabolite association network by combining metabolic pathway topological distance. Based on this, the system integrates pathway constraint betweenness centrality and disease effect size to calculate network-enhanced discriminant scores, performs dimensionality reduction according to the principle of maximum coverage and minimum redundancy, and simultaneously evaluates the stability baseline values ​​of biomarker-related ecological functional modules. Finally, using ecological stability as a constraint, the system optimizes the discriminative power of multiple diseases through marginal contribution evaluation, outputting a balanced and efficient biomarker panel. This invention achieves systematic integration of microbiome and metabolome data, providing a reliable tool for the accurate diagnosis of digestive system diseases.

The application provides an article information pushing method combining article attributes and user preferences, comprising: obtaining digestive system disease types, digestive tract absorption capacity, digestive fluid secretion conditions and physiological characteristic data related to digestive function of a plurality of users, grouping the users through a clustering algorithm to obtain user groups with different digestive function characteristics; obtaining dosage form, particle size and surface area attribute information of health products, reducing the dimensions of the health products through principal component analysis according to disintegration time, dissolution rate and osmotic pressure characteristics of the dosage form to obtain a key attribute set of health products with different dosage forms; obtaining health product information searched by the user and digestive condition data of the user, and judging whether the user belongs to a group with weak digestive tract absorption capacity or a group with normal digestive function according to a set digestive threshold.

An active yeast adapted to weak organic acids and to the use thereof for poultry or cud-chewing animals. Also, a probiotic for poultry or cud-chewing animals, including an active yeast adapted to weak organic acids. Further, the use of such a yeast for improving the zootechnical performances of poultry and to the use thereof in a probiotic and / or food for poultry. Furthermore, the use of such a yeast for improving the physico-chemical and fermentative parameters of the rumen of cud-chewing animals, and to the use thereof in a probiotic and / or food for cud-chewing animals. In addition, a yeast for use in the prevention and / or the treatment of digestive disorders in cud-chewing animals and particularly in the prevention of acidosis in cud-chewing animals.

The invention discloses a digestion health monitoring system based on artificial intelligence, and the system collects multi-source heterogeneous digestion health data in real time through multiple channels, and constructs a structured knowledge system covering the digestive organ structure, the physiological process, the disease symptom and other contents through a knowledge graph technology. And the long-distance dependency relationship of the data is effectively captured by means of an improved Transform-XL model. The system realizes deep interaction between a knowledge graph and coded data, accurately extracts key characteristics of digestive health through a multi-layer neural network, completes health state prediction and evaluation in combination with a professional evaluation model, and performs visual optimization output on a result. Meanwhile, model parameters are dynamically adjusted based on knowledge graph updating, and stable system performance is ensured. The system overcomes the defects of a traditional monitoring means, efficient processing and accurate analysis of digestion health data are achieved, intelligent, real-time and comprehensive digestion health monitoring service is provided for users, and early discovery of digestive system diseases and health management are assisted.

The application provides a method for establishing a digestive system disease multi-modal information diagnosis and treatment system, S1, collecting multi-modal information for labeling and preprocessing; S2, extracting a feature vector and embedding a label to the multi-modal information according to the labeled information; S3, splicing and mapping the feature vector and the label to a unified dimension to obtain an enhanced feature vector; S4, fusing the enhanced feature vector to form a multi-modal feature matrix, performing linear mapping on the multi-modal feature matrix, obtaining a global fusion vector after weighted aggregation, and generating a fusion vector sequence; S5, enhancing the time sequence information of the global fusion vector sequence and the spatial information of the spatial correlation of the part-specific feature; interactive fusion to obtain a space-time joint feature; S6, classifying and predicting the disease stage or specific pathological type, and outputting a diagnosis result; S7, realizing semantic association between the diagnosis result and a medical knowledge graph, sharing data to an online health wisdom platform, and providing personalized decision-making basis for clinical doctors.

The application provides a traditional Chinese medicine composition for improving digestive system diseases caused by brain-gut disorder, which is made of the following traditional Chinese medicines in parts by weight: Gastrodia 1-35 parts, Astragalus 1-35 parts, Fructus Alpiniae oxyphyllae 1-20 parts, Atractylodes 1-20 parts, Hypericum 1-20 parts, Cinnamomum 1-10 parts, and Dried Ginger 1-10 parts, and further provides a preparation method and application of the composition. The traditional Chinese medicine composition can intervene in the brain-gut disorder related digestive system diseases from the perspective of brain-gut interaction, has the effects of improving anxiety and depression-like behaviors, reducing visceral pain sensitivity, protecting and repairing intestinal mucosal barrier, reducing intestinal local inflammatory response, and regulating intestinal flora structure, so as to realize the comprehensive regulation of emotional abnormalities and digestive system symptoms in brain-gut disorder related digestive system diseases, and has a good clinical application prospect.